#DNTH

StockTitan

@stocktitan.net

5 days ago

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering Dianthus Therapeutics (Nasdaq: DNTH) priced an upsized underwritten public offering of 7,313,582 common shares at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999, with aggregate gross proceeds of approximately $625 million before fees.The offering is expected to close on March 12, 2026, and underwriters have a 30-day option to purchase up to an additional 1,157,407 shares. Net proceeds will fund clinical/preclinical programs, commercial readiness, working capital, and general corporate purposes.

#DNTH Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

www.stocktitan.net/news/DNTH/dianthus-thera...

StockTitan

@stocktitan.net

6 days ago

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering Dianthus Therapeutics (Nasdaq: DNTH) announced a proposed underwritten public offering of $400 million of common stock or, for some investors, pre-funded warrants, with a 30-day underwriter option for up to $60 million additional shares. The offering is subject to market and other conditions. Dianthus intends to use net proceeds to advance clinical and preclinical development, commercial readiness activities, and for working capital and general corporate purposes. Joint book-running managers include Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair.

#DNTH Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

www.stocktitan.net/news/DNTH/dianthus-thera...

StockTitan

@stocktitan.net

6 days ago

Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results Dianthus Therapeutics (Nasdaq: DNTH) announced an early GO decision for the Phase 3 CAPTIVATE CIDP trial after achieving 20 confirmed responders with fewer than 40 participants completing open-label Part A. The company reported $514.4 million cash as of December 31, 2025, runway into 2028, full-year R&D of $145.6 million, and a 2025 net loss of $162.3 million. Key development timelines: gMG Phase 3 start mid-2026 (top-line 2H'28), MMN Phase 2 top-line 2H'26, and DNTH212 Phase 1 healthy volunteer data expected 2H'26.

#DNTH Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results

www.stocktitan.net/news/DNTH/dianthus-thera...

StockTitan

@stocktitan.net

4 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results Dianthus Therapeutics (Nasdaq: DNTH) reported Q3 2025 results and business updates highlighting positive clinical progress for claseprubart (DNTH103), the in-licensing of DNTH212, and a strengthened cash position. Key clinical developments include statistically significant Phase 2 MaGic gMG results at Week 13, AANEM data supporting potential 300mg/2mL Q4W dosing, planned Phase 3 gMG initiation in 2026 with two dose arms, accelerated CIDP Phase 3 interim responder analysis to Q2 2026, and ongoing MMN Phase 2 with top-line in 2H’26. Financial highlights: estimated adjusted cash of ~$525M (runway into 2028), R&D of $32.5M in Q3, and net loss of $36.8M (Q3 2025).

#DNTH Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

www.stocktitan.net/news/DNTH/dianthus-thera...

StockTitan

@stocktitan.net

4 months ago

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase 3 gMG trial planned to include QMG ≥ 10 screening criteria and two claseprubart treatment arms,

#DNTH Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting

www.stocktitan.net/news/DNTH/dianthus-thera...

StockTitan

@stocktitan.net

6 months ago

$251 Million Capital Raise: Dianthus Therapeutics Secures Major Funding for Autoimmune Drug Development Clinical-stage biotech Dianthus Therapeutics prices offering of 6.49M shares at $33.00 and 1.11M pre-funded warrants. Proceeds to advance complement therapeutics pipeline for autoimmune diseases.

#DNTH Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering

www.stocktitan.net/news/DNTH/dianthus-thera...

Market Wire News

@marketwirenews.com

6 months ago

Breaking News: ( NASDAQ: #DNTH ) Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

StockTitan

@stocktitan.net

7 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results Dianthus Therapeutics (NASDAQ:DNTH) reported Q2 2025 financial results and business updates, highlighting significant progress in its clinical programs. The company's lead drug candidate claseprubart (DNTH103) is advancing in multiple trials:The Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) completed enrollment with 65 patients, with top-line results expected in September 2025. The Phase 3 CAPTIVATE trial in CIDP and Phase 2 MoMeNtum trial in MMN are progressing with results anticipated in 2H'26.Financially, Dianthus reported $309.1 million in cash, providing runway into 2H'27. Q2 net loss was $31.6 million ($0.88 per share), with R&D expenses of $26.3 million and G&A expenses of $8.9 million.

#DNTH Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

www.stocktitan.net/news/DNTH/dianthus-thera...

StockTitan

@stocktitan.net

10 months ago

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results Dianthus Therapeutics (NASDAQ: DNTH) reported Q1 2025 financial results and business updates. The company completed enrollment for its Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) with 65 patients, exceeding the target of 60. Top-line results are expected in September 2025. Two other trials are ongoing: the Phase 3 CAPTIVATE trial for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the Phase 2 MoMeNtum trial for Multifocal Motor Neuropathy (MMN), both with results expected in 2H'26. Financially, Dianthus reported $331.5 million in cash, providing runway into 2H'27. Q1 2025 saw a net loss of $29.5 million ($0.82 per share), compared to $13.7 million ($0.54 per share) in Q1 2024. R&D expenses increased to $27.0 million from $13.1 million year-over-year, while G&A expenses rose to $7.3 million from $5.6 million.

#DNTH Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

www.stocktitan.net/news/DNTH/dianthus-thera...

StockTitan

@stocktitan.net

10 months ago

Breakthrough gMG Treatment DNTH103 Hits Major Milestone: Phase 2 Results Coming This Fall New self-administered gMG therapy DNTH103 exceeds trial enrollment targets. Discover how this potential first-line treatment could transform patient care. See timeline.

#DNTH Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

www.stocktitan.net/news/DNTH/dianthus-thera...

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

Small-cap stocks with strong volume gains, Mon Mar 17th - #SNCR #QMCO #NIU #LMNR #GES #SES #SOL #YSG #ANNX #CFB #DNTH #GNPX #HYPR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

Dianthus Therapeutics Secures 3-Year Runway with $357M Cash, Pushes Three Critical Trials Forward Dianthus maintains $357M cash runway through 2027, advancing Phase 2/3 trials in gMG, CIDP, and MMN. Key clinical readouts expected starting 2H'25.

#DNTH Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

www.stocktitan.net/news/DNTH/dianthus-thera...